Restricted accessEditorialFirst published online 1995-4
Tavola Rotonda su: “Fattori prognostici e markers nel carcinoma della vescica”. Aspetti generali e introduttivi: Round Table on: “Prognostic factors and markers in bladder carcinoma”. General and introductory aspects
Bladder tumours are generally grouped as superficial or invasive because of their different therapeutical regimens. Superficial tumours still cause uncertainties in choosing the best treatment due to their heterogeneity and different behaviour. In the prevision of these tumours it is important to consider all the factors that could influence the prognosis: tumoral characteristics, grading and staging mistakes, effects of the therapy and immunological response. Moreover it is important for clinical studies to have appropriate end points. Prognostic factors and markers with high predictive value can allow specific treatment for the individual cases to be planned.
FitzpatrickJ.M.: Superficial bladder carcinoma. Factors affecting the natural history. World J. Urol., 11: 142, 1993.
2.
AbelP.D., HallR.R., WilliamsG.: Should pT1 transitional cell cancers of the bladder still be classified as superficial?Br. J. Urol., 62: 235, 1988.
3.
KolozsyZ.: Histopathologic ‘self control’ in transurethral resection of bladder tumors. Br. J. Urol., 67: 162, 1991.
4.
KlanR., LovV., HullandH.: Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J. Urol., 146: 316, 1991.
5.
KhannaO.P., SonD.L., MazerH.: Multicenter study of superficial bladder cancer treated with intravesical BCG or Adriamycin. Urology, 35: 101, 1990.
6.
HerrH. W.: Progression of stage T1 bladder tumours after intravesical bacillus Calmette-Guerin. J. Urol., 145: 40, 1991.
7.
KurthK.H., DenisL., SheuvartE.: Risk groups for tumor invasion and death due to malignant disease in superficial TCC Ta-T1 of the bladder. Urology, 18(Suppl. 1): 4, 1990.
8.
CatalonaW.J., SmolevJ.K., HartyJ.I.: Prognostic value of host immunocompetence in urologic cancer patients. J. Urol., 114: 922, 1975.
9.
FaheyJ.L., BrosmanS., DoreyF.: Immunological responsiveness in patients with bladder cancer. Cancer. Res., 37: 2875, 1977.
10.
HopkinsS.C., FordK.S., SolowayM.S.: Invasive bladder cancer: support for screening. J. Urol., 130: 61, 1983.
11.
KayeK.W., LangeP.H.: Mode of presentation of invasive bladder cancer: reassessment of the problem. J. Urol., 128: 31, 1981.
12.
BrawnP.N.: The origin of invasive carcinoma of the bladder. Cancer, 50: 515, 1982.
13.
SanchezP. De La Muela, RoseliD., AgueraL., De CastroF., IsaW., RoblesJ.E., ZudaireJ.J., BerianJ.M.: Multivariate analysis of progression in superficial bladder cancer. Br. J. Urol., 71: 284, 1993.
14.
KalishL.A., GarnickM.B., RichieJ.P.: Appropriate endpoints for superficial bladder cancer clinical trials. J. Clin. Oncol., 5: 2004, 1987.
